JP2024529430A5 - - Google Patents

Info

Publication number
JP2024529430A5
JP2024529430A5 JP2024504503A JP2024504503A JP2024529430A5 JP 2024529430 A5 JP2024529430 A5 JP 2024529430A5 JP 2024504503 A JP2024504503 A JP 2024504503A JP 2024504503 A JP2024504503 A JP 2024504503A JP 2024529430 A5 JP2024529430 A5 JP 2024529430A5
Authority
JP
Japan
Prior art keywords
cancer
composition according
week
period
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024504503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529430A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/038188 external-priority patent/WO2023009438A1/en
Publication of JP2024529430A publication Critical patent/JP2024529430A/ja
Publication of JP2024529430A5 publication Critical patent/JP2024529430A5/ja
Pending legal-status Critical Current

Links

JP2024504503A 2021-07-26 2022-07-25 がんの処置における使用のための1-(4-{[4-(ジメチルアミノ)ピペリジン-1-イル]カルボニル}フェニル)-3-[4-(4,6-ジモルホリン-4-イル-1,3,5-トリアジン-2-イル)フェニル]尿素(ゲダトリシブ)およびその組合せ Pending JP2024529430A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163225707P 2021-07-26 2021-07-26
US63/225,707 2021-07-26
US202163285327P 2021-12-02 2021-12-02
US63/285,327 2021-12-02
PCT/US2022/038188 WO2023009438A1 (en) 2021-07-26 2022-07-25 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2024529430A JP2024529430A (ja) 2024-08-06
JP2024529430A5 true JP2024529430A5 (cg-RX-API-DMAC7.html) 2025-07-24

Family

ID=82932627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024504503A Pending JP2024529430A (ja) 2021-07-26 2022-07-25 がんの処置における使用のための1-(4-{[4-(ジメチルアミノ)ピペリジン-1-イル]カルボニル}フェニル)-3-[4-(4,6-ジモルホリン-4-イル-1,3,5-トリアジン-2-イル)フェニル]尿素(ゲダトリシブ)およびその組合せ

Country Status (11)

Country Link
US (3) US12350276B2 (cg-RX-API-DMAC7.html)
EP (1) EP4376848A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024529430A (cg-RX-API-DMAC7.html)
KR (1) KR20240040768A (cg-RX-API-DMAC7.html)
AU (2) AU2022320615B2 (cg-RX-API-DMAC7.html)
CA (1) CA3227191A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000208A1 (cg-RX-API-DMAC7.html)
IL (1) IL310243A (cg-RX-API-DMAC7.html)
MX (1) MX2024001266A (cg-RX-API-DMAC7.html)
TW (1) TW202320795A (cg-RX-API-DMAC7.html)
WO (1) WO2023009438A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025049962A1 (en) * 2023-08-31 2025-03-06 Aadi Bioscience, Inc. Combination cancer treatments with a composition comprising an mtor pathway inhibitor
US20260053814A1 (en) * 2024-08-21 2026-02-26 Celcuity Inc. Treatment regimens for gedatolisib in hormonally-driven disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
GB0327380D0 (en) 2003-11-25 2003-12-31 Cyclacel Ltd Method
JP5190271B2 (ja) 2005-01-14 2013-04-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤としての5員の環付加複素環式ピリミジン
US10022381B2 (en) 2008-05-23 2018-07-17 Pfizer Inc. Triazine compounds as PI3 kinase and mTOR inhibitors
MY155653A (en) 2008-05-23 2015-11-13 Wyeth Llc Triazine compounds as p13 kinase and mtor inhibitors
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
KR102186969B1 (ko) 2010-10-25 2020-12-04 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
EP3216792B1 (en) 2012-03-29 2020-05-27 G1 Therapeutics, Inc. Lactam kinase inhibitors
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
EP3116547B1 (en) 2014-03-14 2019-06-05 Pfizer Inc Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
HUE055928T2 (hu) 2014-12-17 2022-01-28 Pfizer PI3K/MTOR-inhibitorok készítményei intravénás adagolásra
LT3672571T (lt) 2017-08-25 2021-12-10 Pfizer Inc. Farmacinė vandeninė vaisto forma, apimanti 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]karbamidą
US12109308B2 (en) 2018-06-07 2024-10-08 Pfizer Inc. Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yljcarbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
EP3863618A1 (en) * 2018-10-08 2021-08-18 F. Hoffmann-La Roche AG Methods of treating cancer with pi3k alpha inhibitors and metformin

Similar Documents

Publication Publication Date Title
JP2023502530A (ja) Hiv予防のためのカプシド阻害剤
KR102644781B1 (ko) 코티코트로핀 방출 인자 수용체 길항제
JP2015512406A5 (cg-RX-API-DMAC7.html)
JP2019529581A5 (cg-RX-API-DMAC7.html)
JP2013529665A5 (cg-RX-API-DMAC7.html)
JP2013544804A5 (cg-RX-API-DMAC7.html)
JP2018529742A5 (cg-RX-API-DMAC7.html)
JP2015536986A5 (cg-RX-API-DMAC7.html)
JP2002505280A (ja) 一過性熱感を軽減するための塩酸フルオキセチン
RU2018136580A (ru) Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты
JP2020527575A5 (cg-RX-API-DMAC7.html)
KR20200026920A (ko) 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법
JP2022552187A5 (cg-RX-API-DMAC7.html)
JP2021512906A5 (cg-RX-API-DMAC7.html)
JP2021516241A5 (cg-RX-API-DMAC7.html)
JP2020504129A (ja) 非アルコール性脂肪性肝炎(nash)および肝線維症のための併用療法
JP2022173567A (ja) 注腸剤
JP7313438B2 (ja) Hivの予防のためのインテグラーゼ阻害剤
JP7376540B2 (ja) リンパ節陽性の初期ホルモン受容体陽性かつヒト上皮成長因子受容体2陰性乳癌の補助治療のための内分泌療法とアベマシクリブとの組み合わせ
CN1262622A (zh) 调节人性反应的联合治疗
JP2023531930A5 (cg-RX-API-DMAC7.html)
TW202304427A (zh) 多激酶抑制劑的藥物組合物及其用途
US20210353648A1 (en) Grapiprant unit dosage forms
JP2023549849A5 (cg-RX-API-DMAC7.html)
JP2024506385A5 (cg-RX-API-DMAC7.html)